DE69214881D1 - Pyridazindione und ihre Verwendung bei der Behandlung von neurologischen Erkrankungen - Google Patents

Pyridazindione und ihre Verwendung bei der Behandlung von neurologischen Erkrankungen

Info

Publication number
DE69214881D1
DE69214881D1 DE69214881T DE69214881T DE69214881D1 DE 69214881 D1 DE69214881 D1 DE 69214881D1 DE 69214881 T DE69214881 T DE 69214881T DE 69214881 T DE69214881 T DE 69214881T DE 69214881 D1 DE69214881 D1 DE 69214881D1
Authority
DE
Germany
Prior art keywords
alkyl
opt
substd
phenyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69214881T
Other languages
English (en)
Other versions
DE69214881T2 (de
Inventor
Thomas Michael Bare
Richard Bruce Sparks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919109973A external-priority patent/GB9109973D0/en
Priority claimed from GB929202991A external-priority patent/GB9202991D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of DE69214881D1 publication Critical patent/DE69214881D1/de
Application granted granted Critical
Publication of DE69214881T2 publication Critical patent/DE69214881T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
DE69214881T 1991-05-09 1992-05-06 Pyridazindione und ihre Verwendung bei der Behandlung von neurologischen Erkrankungen Expired - Fee Related DE69214881T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919109973A GB9109973D0 (en) 1991-05-09 1991-05-09 Therapeutic compositions
GB929202991A GB9202991D0 (en) 1992-02-13 1992-02-13 Compounds

Publications (2)

Publication Number Publication Date
DE69214881D1 true DE69214881D1 (de) 1996-12-05
DE69214881T2 DE69214881T2 (de) 1997-03-13

Family

ID=26298868

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69214881T Expired - Fee Related DE69214881T2 (de) 1991-05-09 1992-05-06 Pyridazindione und ihre Verwendung bei der Behandlung von neurologischen Erkrankungen

Country Status (21)

Country Link
US (4) US5604227A (de)
EP (1) EP0516297B1 (de)
JP (1) JP3279633B2 (de)
KR (1) KR100231095B1 (de)
AT (1) ATE144707T1 (de)
AU (1) AU642086B2 (de)
CA (1) CA2067537A1 (de)
CZ (1) CZ286814B6 (de)
DE (1) DE69214881T2 (de)
DK (1) DK0516297T3 (de)
ES (1) ES2093782T3 (de)
FI (1) FI102754B1 (de)
GB (1) GB9208511D0 (de)
GR (1) GR3021512T3 (de)
HU (2) HUT61302A (de)
IE (1) IE921294A1 (de)
IL (1) IL101711A0 (de)
MY (1) MY108482A (de)
NO (1) NO180619C (de)
NZ (1) NZ242540A (de)
SK (1) SK280336B6 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US5776935A (en) 1996-07-25 1998-07-07 Merz & Co. Gmbh & Co. Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
MXPA01009733A (es) * 1999-03-31 2002-11-04 Basf Ag Diamidas del acido piridin-2,3-dicarboxilico.
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
KR100965861B1 (ko) 2002-10-24 2010-06-24 삼성전자주식회사 이동통신 시스템에서 복합 재전송 제어 장치
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds

Also Published As

Publication number Publication date
FI922099A0 (fi) 1992-05-08
US5733910A (en) 1998-03-31
HU9201486D0 (en) 1992-07-28
KR920021147A (ko) 1992-12-18
CS139692A3 (en) 1992-11-18
ATE144707T1 (de) 1996-11-15
FI102754B (fi) 1999-02-15
MY108482A (en) 1996-09-30
GR3021512T3 (en) 1997-01-31
JPH05140162A (ja) 1993-06-08
HUT61302A (en) 1992-12-28
NO921841D0 (no) 1992-05-08
DK0516297T3 (da) 1997-04-07
GB9208511D0 (en) 1992-06-03
HU211149A9 (en) 1995-10-30
CA2067537A1 (en) 1992-11-10
NO180619C (no) 1997-05-21
NO180619B (no) 1997-02-10
DE69214881T2 (de) 1997-03-13
IE921294A1 (en) 1992-11-18
FI922099A (fi) 1992-11-10
ES2093782T3 (es) 1997-01-01
SK280336B6 (sk) 1999-12-10
NO921841L (no) 1992-11-10
AU642086B2 (en) 1993-10-07
NZ242540A (en) 1994-10-26
IL101711A0 (en) 1992-12-30
AU1521392A (en) 1992-11-12
EP0516297A1 (de) 1992-12-02
US5604227A (en) 1997-02-18
KR100231095B1 (ko) 1999-11-15
US5599814A (en) 1997-02-04
US5739133A (en) 1998-04-14
CZ286814B6 (cs) 2000-07-12
EP0516297B1 (de) 1996-10-30
JP3279633B2 (ja) 2002-04-30
FI102754B1 (fi) 1999-02-15

Similar Documents

Publication Publication Date Title
ATE144707T1 (de) Pyridazindione und ihre verwendung bei der behandlung von neurologischen erkrankungen
TW229156B (de)
ES8400729A1 (es) Procedimiento para la preparacion de nuevos derivados de la aminometil-5-aril-3-oxazolidinona-2.
ATE261722T1 (de) Verwendung von chemotherapeutika zur topischen behandlung
DE3869907D1 (de) Chinolincarbonsaeure-derivate.
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
HK186696A (en) Substituted imidazobenzaze-pines and imidazopyridoaze-pines
ATE132749T1 (de) Behandlung der hepatobilären erkrankung mit 15- ketoprostaglandin-derivaten
DE69124415T2 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
ATE20880T1 (de) Verwendung von basisch substituierten phenylacetonitrilen bei der vorbeugenden bekaempfung von krankheiten.
JPS5618967A (en) Azolyllalkenol* its manufacture and its use as bactericide
EP0675127A4 (de) Chinolincarbonsäurederivate und verfahren zu ihrer herstellung.
ATE146964T1 (de) Behandlung von katarakt mit prostacyclinverbindungen
FR2021123A1 (fr) Nouveaux derives du 1,3-diamino-propane-2-ol
EP0097468A3 (de) Thio-naphthotriazole, Verfahren zu ihrer Herstellung und Verwendung bei der Behandlung von Allergien
ATE132748T1 (de) Verwendung eines dihydropyridins zur verbesserung der blutzirkulation des inneren ohres

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTRAZENECA UK LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee